医药导报2026，Vol.45Issue(8)：1293-1314,22.DOI:10.3870/j.issn.1004-0781.2026.08.001
胃肠外直接凝血酶抑制剂临床应用专家共识
Expert Consensus on the Clinical Application of Parenteral Direct Thrombin Inhibitors
摘要
Abstract
With the continuous development of anticoagulant drugs,parenteral direct thrombin inhibitors(DTIs)for thromboembolic diseases have gradually attracted widespread attention in the medical field.The consensus group aim to formulate clinical recommendations for parenteral DTIs based on evidence-based medical evidence,and further standardize the rational use of parenteral DTIs in the prevention and treatment of thromboembolic diseases in China.According to the guidelines of the World Health Organization,20 clinical questions were selected through literature research and Delphi questionnaire survey.Systematic searches of domestic and foreign databases were conducted and the current best evidence-based evidence was integrated.The quality of evidence was comprehensively evaluated using the recommendation grading assessment,formulation and evaluation system,and recommendations were formed through 3 rounds of Delphi surveys and expert consensus meetings.A total of 19 recommendations were formed in the"Expert Consensus on the Clinical Application of Parenteral Direct Thrombin Inhibitors".The formulation of this consensus promotes the standardized application of parenteral DTIs in China and provides a reference for clinicians and pharmacists to formulate individualized medication plans.关键词
胃肠外直接凝血酶抑制剂/血栓栓塞/临床应用/循证用药/专家共识Key words
Parenteral direct thrombin inhibitor/Thromboembolism/Clinical application/Evidence-based medication/Expert consensus分类
医药卫生引用本文复制引用
中国心胸血管麻醉学会心血管药学分会,成都药学会血栓与止血专委会,边原..胃肠外直接凝血酶抑制剂临床应用专家共识[J].医药导报,2026,45(8):1293-1314,22.基金项目
四川省科技厅自然科学基金资助项目(2022NSFSC0818) （2022NSFSC0818）
个体化药物治疗四川省重点实验室开放课题(2021ZD01) （2021ZD01）
四川省食品药品监督管理局项目(2024012) （2024012）
四川省食品药品审查评价及安全监测中心药物警戒开放课题(YWJJ202501). （YWJJ202501）
